What Current Reports Say About Ozempic and Gastroparesis in New Jersey

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Concern

If you or a loved one has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. Decades of pharmacovigilance have documented delayed gastric emptying as a recognized side effect of GLP-1 receptor agonists. This page summarizes current FDA label warnings and clinical reports relevant to New Jersey residents.

Find Out If You Qualify for Compensation →

Medical Evidence: Ozempic and Gastroparesis

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, symptom assessment, and exclusion of other causes. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacology includes slowing gastric emptying, which is a mechanism that contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these adverse reaction tables, the mechanistic pathway linking Ozempic to gastroparesis is biologically plausible: GLP-1 receptor agonists delay gastric emptying, and in susceptible individuals, this effect may become pathological, leading to symptomatic gastroparesis. The reported gastrointestinal adverse reactions, particularly nausea, vomiting, and dyspepsia, overlap with gastroparesis symptoms, and prolonged use may contribute to the development or exacerbation of the condition.

Legal Considerations: Statute of Limitations in New Jersey

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions, such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a potential adverse effect. This gap may be relevant for patients who develop gastroparesis after using Ozempic, as they may argue that the manufacturer failed to provide adequate warnings about a known or foreseeable risk. For affected patients in New Jersey, attorney-related considerations include the statute of limitations for product liability claims. In New Jersey, the statute of limitations for personal injury claims, including those based on defective drugs, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is crucial for patients who develop gastroparesis after using Ozempic, as they must file a claim within this period. The timeline between exposure to Ozempic and documented harm is also important. Gastroparesis may develop gradually, and symptoms may not be immediately recognized as drug-related. Patients should document the start date of Ozempic use, the onset of gastrointestinal symptoms, and any medical diagnoses of gastroparesis. Medical records, including gastric emptying studies and physician notes, can help establish the temporal relationship. In summary, the evidence indicates that Ozempic is associated with a higher incidence of gastrointestinal adverse reactions, including symptoms that overlap with gastroparesis. The mechanistic link through delayed gastric emptying supports the plausibility of Ozempic causing or contributing to gastroparesis. The adequacy of warnings is questionable, as the label does not specifically mention gastroparesis. Patients in New Jersey should be aware of the two-year statute of limitations and the importance of documenting the timeline of exposure and harm. Legal consultation is recommended for those considering a claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including product liability claims related to defective drugs, is generally two years from the date the injury was discovered or reasonably should have been discovered. For Ozempic-related gastroparesis, this means you must file a claim within two years of when you knew or should have known that your gastroparesis was linked to Ozempic use.

Does Ozempic cause gastroparesis?

While Ozempic's prescribing information does not explicitly list gastroparesis as a side effect, the drug's mechanism of action—slowing gastric emptying—makes it biologically plausible that it could cause or contribute to gastroparesis in susceptible individuals. Clinical trials show a higher incidence of gastrointestinal adverse reactions such as nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms. If you have developed gastroparesis after taking Ozempic, it is important to consult a medical professional and an attorney.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.